HopeStage
Back to all studies
CompletedNCT02517424

Vaporized Cannabis for Chronic Treatment-Resistant PTSD

About this title

Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder

Read the official source — NCT02517424
Medication studyAges 18+Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
KelownaSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: February 7, 2017
Recruitment status
Completed
Enrollment listed in the registry
6
Sponsor
Tilray
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Canada
Age range
Over 18 Years
Official registry ID
NCT02517424
Official title
Show the full official title

Placebo-Controlled, Triple-Blind, Crossover Study of the Safety and Efficacy of Three Different Potencies of Vaporized Cannabis in 42 Participants With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Kelowna

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Tilray.

Did this study involve medication?

Yes. The study involved medication, including High THC/Low CBD Cannabis, High THC/High CBD Cannabis and Low THC/Low CBD Cannabis.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies